DK2323647T3 - Langtidsbehandling af symptomatisk hjerteinsufficiens - Google Patents
Langtidsbehandling af symptomatisk hjerteinsufficiens Download PDFInfo
- Publication number
- DK2323647T3 DK2323647T3 DK09777388.1T DK09777388T DK2323647T3 DK 2323647 T3 DK2323647 T3 DK 2323647T3 DK 09777388 T DK09777388 T DK 09777388T DK 2323647 T3 DK2323647 T3 DK 2323647T3
- Authority
- DK
- Denmark
- Prior art keywords
- pufa
- patients
- use according
- epa
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Magnetic Heads (AREA)
- Meat, Egg Or Seafood Products (AREA)
Claims (8)
1.
n-3 PUFA til anvendelse til behandling af symptomatisk hjerteinsufficiens hos patienter med en venstre ventrikel-uddrivningsfraktion <40% (LVEF <40%), diabetes og/eller totalcholesterol <200 mg/dl, fortrinsvis £188 mg/dl, for at reducere mortalitet eller hospitalsindlæggelse afen kardiovaskulær årsag, hvor n-3 PUFA er en blanding affedtsyrer med et indhold af EPA og DFIA på mellem 75 og 95 vægtprocent baseret på den samlede fedtsyrevægt, og hvor det pågældende n-3 PUFA administreres til patienterne i mere end 3,5 år.
2.
n-3 PUFA til anvendelsen ifølge krav 1, hvor n-3 PUFA er en blanding af fedtsyrer med et indhold af EPA og DHA på mindst 85 vægtprocent baseret på den samlede fedtsyrevægt, og det samlede indhold af n-3 PUFA er mindst 90 vægtprocent baseret på den samlede fedtsyrevægt.
3.
n-3 PUFA til anvendelsen ifølge krav 1, hvor n-3 PUFA er en blanding af ethylestere af EPA og DHA i et forhold på mellem 0,9 og 1,5, og indholdet af EPA-ethylester ligger på mellem 40 og 51 vægtprocent, og indholdet af DHA-ethylester ligger på mellem 34 og 45 vægtprocent baseret på den samlede fedtsyrevægt.
4.
n-3 PUFA til anvendelsen ifølge et hvilket som helst af de foregående krav, hvor dosen af n-3 PUFA, der skal administreres til en patient med symptomatisk hjerteinsufficiens, er en daglig oral dosis på 1 g. 5. n-3 PUFA til anvendelsen ifølge et hvilket som helst af de foregående krav, som endvidere omfatter et eller flere yderligere midler til administration i kombination, det vil sige enten sammen eller separat, i det væsentlige samtidig eller sekventielt med n-3 PUFA. 1 6. n-3 PUFA til anvendelsen ifølge krav 5, hvor det terapeutiske middel er valgt fra gruppen bestående af: ACE-hæmmere, NEP-hæmmere, ACE/NEP-hæmmere, hæmmere af angiotensin l-konverterende enzym, diuretika, positivt inotrope lægemidler, phosphodiesterasehæmmere, arteriolære og venolære vasodilatatorer, betablokkere og digitalisglycosider eller en blanding deraf. 7. n-3 PUFA til anvendelsen ifølge krav 6, hvor det terapeutiske middel er et statin. 8. n-3 PUFA til anvendelsen ifølge krav 7, hvor statinet er valgt fra gruppen bestående af: simvastatin, lovastatin, fluvastatin, pravastatin, atorvastatin, cerivastatin, rovastatin og rosuvastatin. 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08161994 | 2008-08-07 | ||
| PCT/EP2009/005347 WO2010015335A1 (en) | 2008-08-07 | 2009-07-23 | Long-term treatment of symptomatic heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2323647T3 true DK2323647T3 (da) | 2014-12-08 |
Family
ID=40101155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09777388.1T DK2323647T3 (da) | 2008-08-07 | 2009-07-23 | Langtidsbehandling af symptomatisk hjerteinsufficiens |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8592439B2 (da) |
| EP (1) | EP2323647B1 (da) |
| JP (1) | JP5563573B2 (da) |
| KR (1) | KR20110058775A (da) |
| CN (1) | CN102149376B (da) |
| AU (1) | AU2009278317B2 (da) |
| BR (1) | BRPI0917403A2 (da) |
| CA (1) | CA2732071C (da) |
| CY (1) | CY1115785T1 (da) |
| DK (1) | DK2323647T3 (da) |
| EA (1) | EA020237B1 (da) |
| ES (1) | ES2524596T3 (da) |
| HK (1) | HK1160790A1 (da) |
| HR (1) | HRP20141149T1 (da) |
| MX (1) | MX2011001419A (da) |
| PL (1) | PL2323647T3 (da) |
| PT (1) | PT2323647E (da) |
| RS (1) | RS53694B1 (da) |
| SI (1) | SI2323647T1 (da) |
| SM (1) | SMT201500019B (da) |
| WO (1) | WO2010015335A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012108379A1 (ja) | 2011-02-07 | 2012-08-16 | 持田製薬株式会社 | 拡張性うっ血性心不全治療剤 |
| EP2798551A2 (en) * | 2011-12-27 | 2014-11-05 | Koninklijke Philips N.V. | Method and system for reducing early readmission |
| RU2741965C2 (ru) | 2014-06-06 | 2021-02-01 | Мэрин Ингридиэнтс, Ллк | Композиции c омега-3, лекарственные формы и способы их применения |
| WO2019022436A2 (ko) * | 2017-07-27 | 2019-01-31 | 에리슨제약(주) | Nep 저해제 및 베타-차단제를 포함하는 약제학적 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2218984B (en) | 1988-05-27 | 1992-09-23 | Renafield Limited | Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses |
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| CN1082909A (zh) | 1993-01-03 | 1994-03-02 | 潘玉珍 | 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂 |
| US5760081A (en) | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
| US5541225A (en) * | 1994-10-11 | 1996-07-30 | The General Hospital Corporation | α-Linolenic acid and eicosatetraynoic acid in the prevention and treatment of ventricular tachyarrhythmia |
| IT1277953B1 (it) | 1995-12-21 | 1997-11-12 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per |
| IT1308613B1 (it) * | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
| ITMI20010129A1 (it) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| ITMI20012384A1 (it) | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
| US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| JP2010506841A (ja) * | 2006-10-13 | 2010-03-04 | リライアント・ファーマシューティカルズ・インコーポレイテッド | 抗不整脈薬およびオメガ−３脂肪酸およびそれらの組合せ品による治療法 |
-
2009
- 2009-07-23 MX MX2011001419A patent/MX2011001419A/es active IP Right Grant
- 2009-07-23 EA EA201100143A patent/EA020237B1/ru not_active IP Right Cessation
- 2009-07-23 CN CN2009801356010A patent/CN102149376B/zh not_active Expired - Fee Related
- 2009-07-23 CA CA2732071A patent/CA2732071C/en active Active
- 2009-07-23 PT PT97773881T patent/PT2323647E/pt unknown
- 2009-07-23 US US13/057,492 patent/US8592439B2/en active Active
- 2009-07-23 ES ES09777388.1T patent/ES2524596T3/es active Active
- 2009-07-23 KR KR1020117002755A patent/KR20110058775A/ko active Search and Examination
- 2009-07-23 JP JP2011521456A patent/JP5563573B2/ja not_active Expired - Fee Related
- 2009-07-23 AU AU2009278317A patent/AU2009278317B2/en not_active Ceased
- 2009-07-23 RS RS20140649A patent/RS53694B1/en unknown
- 2009-07-23 BR BRPI0917403A patent/BRPI0917403A2/pt not_active IP Right Cessation
- 2009-07-23 WO PCT/EP2009/005347 patent/WO2010015335A1/en active Application Filing
- 2009-07-23 EP EP09777388.1A patent/EP2323647B1/en active Active
- 2009-07-23 PL PL09777388T patent/PL2323647T3/pl unknown
- 2009-07-23 DK DK09777388.1T patent/DK2323647T3/da active
- 2009-07-23 SI SI200931073T patent/SI2323647T1/sl unknown
-
2012
- 2012-02-09 HK HK12101284.9A patent/HK1160790A1/xx not_active IP Right Cessation
-
2014
- 2014-11-25 HR HRP20141149AT patent/HRP20141149T1/hr unknown
- 2014-11-26 CY CY20141100980T patent/CY1115785T1/el unknown
-
2015
- 2015-01-21 SM SM201500019T patent/SMT201500019B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011529928A (ja) | 2011-12-15 |
| WO2010015335A1 (en) | 2010-02-11 |
| US20110178111A1 (en) | 2011-07-21 |
| KR20110058775A (ko) | 2011-06-01 |
| MX2011001419A (es) | 2011-05-25 |
| PT2323647E (pt) | 2014-12-16 |
| CA2732071C (en) | 2018-02-13 |
| BRPI0917403A2 (pt) | 2015-12-01 |
| AU2009278317B2 (en) | 2014-12-18 |
| EA201100143A1 (ru) | 2011-10-31 |
| SI2323647T1 (sl) | 2015-01-30 |
| WO2010015335A8 (en) | 2010-04-29 |
| HK1160790A1 (en) | 2012-08-17 |
| CY1115785T1 (el) | 2017-01-25 |
| ES2524596T3 (es) | 2014-12-10 |
| US8592439B2 (en) | 2013-11-26 |
| CA2732071A1 (en) | 2010-02-11 |
| AU2009278317A8 (en) | 2011-03-31 |
| CN102149376A (zh) | 2011-08-10 |
| EP2323647A1 (en) | 2011-05-25 |
| JP5563573B2 (ja) | 2014-07-30 |
| EA020237B1 (ru) | 2014-09-30 |
| CN102149376B (zh) | 2013-12-25 |
| HRP20141149T1 (hr) | 2015-02-13 |
| EP2323647B1 (en) | 2014-09-10 |
| SMT201500019B (it) | 2015-03-05 |
| PL2323647T3 (pl) | 2015-03-31 |
| RS53694B1 (en) | 2015-04-30 |
| AU2009278317A1 (en) | 2010-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11439618B2 (en) | Compositions and methods for lowering triglycerides | |
| US10973796B2 (en) | Compositions and methods for lowering levels of high-sensitivity C-reactive protein (hs-CRP) in a subject | |
| JP4731789B2 (ja) | 大心血管イベントの一次予防のための多価不飽和脂肪酸の使用 | |
| JP2022062151A5 (da) | ||
| TW201900160A (zh) | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 | |
| JPWO2009142242A1 (ja) | ハイリスク患者の心血管イベント予防用組成物 | |
| KR20080094073A (ko) | 뇌졸중 재발 예방용 조성물 | |
| NO328797B1 (no) | Anvendelse av essensielle fettsyrer inneholdende en blanding av eikosapentaensyreetylester (EPA) og docosaheksaensyreetylester (DHA) for fremstilling av et medikament nyttig ved forebyggelse av dodsfall hos en pasient som har hatt et hjerteinfarkt. | |
| DK2323647T3 (da) | Langtidsbehandling af symptomatisk hjerteinsufficiens | |
| EP2517697B1 (en) | Combination composition useful for treating cardiovascular diseases | |
| US11819511B2 (en) | Composition of N-palmitoyl-ethanolamide and Rutin in co-micronized form | |
| Trimarco | Omega-3 in antiarrhythmic therapy: pros position | |
| JP2007532605A (ja) | 冠性心疾患または冠状動脈疾患を持つ患者の鬱病の予防および／または治療における必須脂肪酸 | |
| KR20190009321A (ko) | 혈관 염증의 치료 또는 혈관 내피 기능 개선에 있어서의 트리아세틸-3-하이드록시 페닐 아데노신의 용도 | |
| NZ727028B2 (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels |